Kennondale Capital Management LLC Stoke Therapeutics, Inc. Transaction History
Kennondale Capital Management LLC
- $91.7 Billion
- Q1 2025
A detailed history of Kennondale Capital Management LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Kennondale Capital Management LLC holds 42,100 shares of STOK stock, worth $408,369. This represents 0.31% of its overall portfolio holdings.
Number of Shares
42,100Holding current value
$408,369% of portfolio
0.31%Shares
1 transactions
Others Institutions Holding STOK
# of Institutions
137Shares Held
56.8MCall Options Held
5.7KPut Options Held
24.4K-
Skorpios Trust6.91MShares$67 Million99.7% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$52.5 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.19MShares$50.3 Million22.22% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$49.7 Million0.92% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$44.9 Million0.57% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $382M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...